- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
35
35 companies
Zevra Therapeutics
Market Cap: US$595.3m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.07
7D
-0.1%
1Y
25.9%
Madrigal Pharmaceuticals
Market Cap: US$11.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$513.72
7D
0.3%
1Y
62.8%
Travere Therapeutics
Market Cap: US$4.1b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$44.12
7D
8.9%
1Y
108.6%
Syndax Pharmaceuticals
Market Cap: US$1.7b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$19.11
7D
-10.7%
1Y
39.2%
Insmed
Market Cap: US$28.8b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$133.26
7D
-1.4%
1Y
84.3%
Rhythm Pharmaceuticals
Market Cap: US$5.6b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$81.81
7D
-4.5%
1Y
27.8%
AnaptysBio
Market Cap: US$1.9b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$66.76
7D
13.4%
1Y
215.1%
Ardelyx
Market Cap: US$1.7b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.88
7D
15.6%
1Y
66.6%
Pelthos Therapeutics
Market Cap: US$83.9m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$25.00
7D
8.4%
1Y
98.4%
Aldeyra Therapeutics
Market Cap: US$95.7m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.59
7D
2.6%
1Y
-43.4%
Capricor Therapeutics
Market Cap: US$1.8b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$30.91
7D
-12.4%
1Y
160.6%
ARS Pharmaceuticals
Market Cap: US$850.0m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.56
7D
3.3%
1Y
-40.8%
CG Oncology
Market Cap: US$5.8b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$66.27
7D
-3.5%
1Y
128.1%
Arcutis Biotherapeutics
Market Cap: US$2.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.35
7D
0.4%
1Y
53.2%
Verrica Pharmaceuticals
Market Cap: US$107.7m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.27
7D
-10.2%
1Y
33.7%
Neurocrine Biosciences
Market Cap: US$13.3b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$131.78
7D
3.2%
1Y
20.1%
SIGA Technologies
Market Cap: US$329.6m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.60
7D
0.7%
1Y
-18.3%
Belite Bio
Market Cap: US$6.1b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$154.85
7D
-4.0%
1Y
147.1%
Praxis Precision Medicines
Market Cap: US$9.0b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$324.20
7D
-6.0%
1Y
705.7%
BeOne Medicines
Market Cap: US$32.7b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$293.86
7D
-2.3%
1Y
14.9%
Citius Pharmaceuticals
Market Cap: US$19.0m
A biopharmaceutical company, focuses on the development and commercialization of critical care products.
CTXR
US$0.70
7D
-9.1%
1Y
-9.0%
Arcellx
Market Cap: US$6.8b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$115.07
7D
0.02%
1Y
75.6%
Mirum Pharmaceuticals
Market Cap: US$5.9b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$96.53
7D
5.5%
1Y
120.9%
Benitec Biopharma
Market Cap: US$409.3m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$11.95
7D
-3.4%
1Y
-20.6%
Gyre Therapeutics
Market Cap: US$712.2m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.80
7D
4.8%
1Y
-15.8%
Journey Medical
Market Cap: US$141.8m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$5.19
7D
0.8%
1Y
-26.2%
Fortress Biotech
Market Cap: US$75.0m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.33
7D
0%
1Y
27.3%
Fennec Pharmaceuticals
Market Cap: US$225.5m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.54
7D
-4.4%
1Y
3.8%
Dyadic International
Market Cap: US$28.8m
A biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.
DYAI
US$0.79
7D
-8.1%
1Y
-34.1%
Protagonist Therapeutics
Market Cap: US$6.3b
Operates as a discovery and development company in the United States.
PTGX
US$98.37
7D
-1.6%
1Y
116.2%
Geron
Market Cap: US$1.0b
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.58
7D
5.3%
1Y
14.5%
Prothena
Market Cap: US$572.8m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$10.64
7D
-1.0%
1Y
25.2%
Inovio Pharmaceuticals
Market Cap: US$90.1m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$1.10
7D
-4.3%
1Y
-42.7%
Legend Biotech
Market Cap: US$4.4b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$23.59
7D
-1.3%
1Y
-28.9%
Alpha Cognition
Market Cap: US$129.6m
A biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
ACOG
US$5.95
7D
-13.2%
1Y
-6.9%